Satellos Bioscience Inc. Announces Encouraging Functional Data from the 28-Day Phase 1B Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

Published: 2025-05-22 08:20:44 ET MSCL.TO

Published on 05/22/2025 at 08:20

Satellos Bioscience Inc. announced promising Phase 1b data, in an open-label study treating five adult male DMD patients, ages 20 - 27, demonstrating early signs that SAT-3247 may have the potential to affect grip strength, which could represent a clinically meaningful measure for patients with DMD. The study focused on adults, a demographic representing individuals who have reached the later stages of the disease, where clinical management becomes increasingly complex and long-term survival is less common. All participants were maintained on their prescribed daily course of steroids during the study.

Summary of clinical results: SAT-3247 appeared to be safe and well tolerated in all study participants. The PK profile of SAT-3247 translated as expected to DMD patients on steroids, an important objective of the study. Satellos believes the Phase 1b findings support advancing SAT-3247 into a global, placebo-controlled Phase 2 proof-of-concept study in pediatric patients, for which global regulatory submissions are planned for the third quarter of 2025.

The Phase 1 clinical trial of SAT-3247 was comprised of two components. In the first component, Phase 1a, 72 healthy volunteers were enrolled in a blinded, randomized, placebo-controlled, staggered, parallel design study to assess the safety and pharmacokinetic properties of SAT-3247.